IL307393A - Combination therapies used in PRMT5 inhibitors to treat cancer - Google Patents

Combination therapies used in PRMT5 inhibitors to treat cancer

Info

Publication number
IL307393A
IL307393A IL307393A IL30739323A IL307393A IL 307393 A IL307393 A IL 307393A IL 307393 A IL307393 A IL 307393A IL 30739323 A IL30739323 A IL 30739323A IL 307393 A IL307393 A IL 307393A
Authority
IL
Israel
Prior art keywords
alkyl
cancer
inhibitor
hydrogen
methyl
Prior art date
Application number
IL307393A
Other languages
English (en)
Hebrew (he)
Inventor
Lars Daniel Engstrom
Peter Olson
James Gail Christensen
Original Assignee
Mirati Therapeutics Inc
Lars Daniel Engstrom
Peter Olson
James Gail Christensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc, Lars Daniel Engstrom, Peter Olson, James Gail Christensen filed Critical Mirati Therapeutics Inc
Publication of IL307393A publication Critical patent/IL307393A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307393A 2021-04-08 2022-04-05 Combination therapies used in PRMT5 inhibitors to treat cancer IL307393A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172643P 2021-04-08 2021-04-08
US202163253029P 2021-10-06 2021-10-06
PCT/US2022/023388 WO2022216645A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL307393A true IL307393A (en) 2023-12-01

Family

ID=81748438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307393A IL307393A (en) 2021-04-08 2022-04-05 Combination therapies used in PRMT5 inhibitors to treat cancer

Country Status (9)

Country Link
US (2) US12171765B2 (https=)
EP (1) EP4319753A1 (https=)
JP (1) JP2024513494A (https=)
KR (1) KR20230167050A (https=)
AU (1) AU2022254651A1 (https=)
CA (1) CA3214535A1 (https=)
IL (1) IL307393A (https=)
MX (1) MX2023011853A (https=)
WO (1) WO2022216645A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
WO2023098439A1 (zh) * 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物，其制备方法和在药学上的应用
WO2023125540A1 (zh) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 吡唑-1(2h)-酞嗪酮类化合物及其应用
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024177416A1 (ko) * 2023-02-22 2024-08-29 단국대학교 천안캠퍼스 산학협력단 Egfr 표적치료제 내성암 치료용 약학 조성물
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025157288A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268044A2 (en) * 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
JP2021176819A (ja) 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
IL290341B2 (en) 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물

Also Published As

Publication number Publication date
KR20230167050A (ko) 2023-12-07
US20250073241A1 (en) 2025-03-06
JP2024513494A (ja) 2024-03-25
MX2023011853A (es) 2023-12-07
AU2022254651A1 (en) 2023-11-02
EP4319753A1 (en) 2024-02-14
CA3214535A1 (en) 2022-10-13
US20220331323A1 (en) 2022-10-20
US12171765B2 (en) 2024-12-24
WO2022216645A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
IL307392A (en) Combination therapies with PRMT5 inhibitors for cancer treatment
IL307393A (en) Combination therapies used in PRMT5 inhibitors to treat cancer
IL281348B1 (en) Combination of SHP-2 inhibitor and KRAS inhibitor G12C for cancer treatment
JP5372751B2 (ja) Ａｚａ−ペプチドプロテアーゼ阻害剤
JP2025000629A (ja) 組み合わせ療法
JP2024540839A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
IL311663A (en) Use of PRMT5 inhibitors to treat cancer
CN112979528B (zh) 一种替加色罗水溶性有机酸盐及其制备方法与应用
IL323718A (en) Combination therapy including a parg inhibitor and a topoisomerase inhibitor for cancer treatment
IL322651A (en) Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
EP4580628A1 (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
US12337004B2 (en) Coumarin-modified androgens for the treatment of prostate cancer
US20250312344A1 (en) Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025217015A1 (en) Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
EA051338B1 (ru) Комбинированная терапия с использованием ингибиторов prmt5 для лечения рака
CN117769420A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
HK40097059A (zh) 用於治疗癌症的5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]-胆甾烷-3β-醇类似物及包含其的药物组合物